Left ventricular ejection fraction is associated with prevalent and incident cardiovascular disease in patients with intermittent claudication - results from the CAVASIC Study.

[1]  P. Hedberg,et al.  Left ventricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease , 2014, European journal of heart failure.

[2]  E. Herrmann,et al.  Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. , 2014, Journal of the American College of Cardiology.

[3]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[4]  F. Kronenberg,et al.  Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: results from the CAVASIC study. , 2013, Clinical chemistry.

[5]  David M. Herrington,et al.  Prognosis of Individuals With Asymptomatic Left Ventricular Systolic Dysfunction in the Multi-Ethnic Study of Atherosclerosis (MESA) , 2012, Circulation.

[6]  Eric E. Smith,et al.  2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standar , 2012, Circulation.

[7]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[8]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[9]  Jeroen J. Bax,et al.  Influence of left ventricular dysfunction (diastolic versus systolic) on long-term prognosis in patients with versus without diabetes mellitus having elective peripheral arterial surgery. , 2010, The American journal of cardiology.

[10]  A. Khera,et al.  Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. , 2009, American heart journal.

[11]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[12]  O. Wagner,et al.  Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study. , 2009, Clinical chemistry.

[13]  F. Kronenberg,et al.  Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. , 2008, Clinical chemistry.

[14]  P. Pellikka,et al.  Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. , 2007, Journal of vascular surgery.

[15]  Jeroen J. Bax,et al.  Improving risk assessment with cardiac testing in peripheral arterial disease. , 2007, The American journal of medicine.

[16]  R. Lang,et al.  Comparison of the frequency of abnormal cardiac findings by echocardiography in patients with and without peripheral arterial disease. , 2007, The American journal of cardiology.

[17]  J. Rehfeld,et al.  Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. , 2006, European heart journal.

[18]  F. Kronenberg,et al.  Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. , 2006, European heart journal.

[19]  M. Chiariello,et al.  Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study , 2006, Journal of cardiovascular medicine.

[20]  S. Yusuf,et al.  Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. , 2006, Journal of the American College of Cardiology.

[21]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[22]  J. Min,et al.  High prevalence of important cardiac findings in patients with peripheral arterial disease referred for echocardiography. , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[23]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[24]  K. Khunti,et al.  Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. , 2005, Journal of the American College of Cardiology.

[25]  P. Shekelle,et al.  Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. , 2004, Journal of the American College of Cardiology.

[26]  D. Levy,et al.  Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.

[27]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[28]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[29]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[30]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[31]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[32]  M. Jensen-Urstad,et al.  Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy. , 1998, The American journal of cardiology.

[33]  N. Kennedy,et al.  Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. , 1996, The American journal of cardiology.

[34]  G. Thorgeirsson,et al.  A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol--the Reykjavik Study. , 1994, Journal of clinical epidemiology.

[35]  E. Vicaut,et al.  Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery. , 1994, The New England journal of medicine.

[36]  G. Lamas,et al.  Ventricular remodeling after myocardial infarction. , 1993, Advances in experimental medicine and biology.

[37]  E. Rose,et al.  Prognostic value of noninvasive cardiac tests in the assessment of patients with peripheral vascular disease. , 1993, The American journal of cardiology.

[38]  B. Pitt,et al.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.

[39]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[40]  J. Ricco.  Intermittent claudication, heart disease risk factors, and mortality: Smith GD, Shipley MJ, Rose G. Circulation 1990;82: 1925–1931 , 1992 .

[41]  M J Shipley,et al.  Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. , 1990, Circulation.

[42]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[43]  R. Schwartz,et al.  Superiority of visual versus computerized echocardiographic estimation of radionuclide left ventricular ejection fraction. , 1989, American heart journal.

[44]  M. Bousser,et al.  Fate of the patient with chronic leg ischaemia. A review article. , 1989, The Journal of cardiovascular surgery.

[45]  Jain Km,et al.  Preoperative cardiac screening before peripheral vascular operations. , 1985 .

[46]  N. Hertzer,et al.  Coronary Artery Disease in Peripheral Vascular Patients: A Classification of 1000 Coronary Angiograms and Results of Surgical Management , 1984, Annals of surgery.